

1542
#4
Dmt
8-1-03



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: William H. Fleming

Art Unit: 1642

Application No. 10/019,165

Filed: December 20, 2001


For: METHOD FOR ENHANCING
HEMATOPOIESIS

Examiner: To be assigned

Date: May 28, 2003

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on May 28, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450.


Susan Robert Stiegel, Ph.D.
Agent for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

RECEIVED

COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

JUN 0 4 2003

TECH CENTER 1600/2900

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent. The filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.


Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit

Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	899-61868
Application Number	10/019,165
Filing Date	December 20, 2001
First Named Inventor	Fleming
Art Unit	1642
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,637,323	06/10/1997	Wiltrout et al.
		5,643,741	07/01/1997	Tsukamoto et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 98/12304 A	03/26/1998	WIPO
		EP 0 730 849 A	09/11/1996	

RECEIVED
JUN 0 4 2003
TECH CENTER 1600/2900

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Grimee and Wulfert., "Acute stress in rats produces a rapid and sustained increase in prostacyclin production in aortic tissue: dependence on corticosterone," <i>Life Sciences</i> Vol. 57, No. 1, pp. 69-81, 1995.
		Ohlstein et al., "SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist," <i>Proceedings of the National Academy of Sciences of the United States</i> Vol. 91, pp. 8052-8056, 1994.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.